Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea

被引:3
|
作者
Kim, Siin [1 ]
Kim, Hyungtae [1 ]
Kim, Eunju [1 ]
Han, Sola [1 ]
Rane, Pratik P. [2 ]
Fox, Kathleen M. [3 ]
Zhao, Zhongyun [2 ]
Qian, Yi [2 ]
Suh, Hae Sun [1 ]
机构
[1] Pusan Natl Univ, Coll Pharm, Busan, South Korea
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Strateg Healthcare Solut LLC, Aiken, SC USA
关键词
adherence; atherosclerotic cardio-vascular disease; diabetes; statin; statin intolerance; treatment pattern; LONG-TERM PERSISTENCE; STATIN THERAPY; ADHERENCE; RISK; NONADHERENCE; TERMINOLOGY; ASSOCIATION; CHOLESTEROL; MANAGEMENT; OUTCOMES;
D O I
10.1016/j.clinthera.2018.04.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: We aimed to study the utilization patterns of lipid-lowering treatment (LLT), including treatment modification, adherence, and possible statin intolerance , in patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes using national claims data in South Korea. Methods: A retrospective cohort study was conducted using data from the Korean Health Insurance Review & Assessment Service claims database. Patients aged >= 18 years with > 1 outpatient pharmacy claim for a statin and/or ezetimibe dated January 1, 2012, to December 31, 2014, were identified and categorized into the following cohorts: patients with ASCVD, and patients with diabetes mellitus without ASCVD. LLT modification, adherence to index LLT, and possible statin intolerance were explored during the 12 months after the date of first prescription for a statin and/or ezetimibe. Findings: Among 1,399,872 patients who met the eligibility criteria, 807,547 (57.7%) were patients with ASCVD and 592,325 (42.3%) were patients with diabetes without ASCVD. About half of the patients had no modification in their index treatment (46.2% in the ASCVD cohort and 48.9% in the diabetes cohort), and the most common modification was permanent discontinuation (19.6% in the ASCVD cohort and 21.4% in the diabetes cohort). The mean medication possession ratios were 0.77 in the ASCVD cohort and 0.73 in the diabetes cohort and showed a decreasing trend during the 12-month follow-up period. Among patients who initiated a statin and/or ezetimibe, possible statin intolerance was observed in 53,921 patients (6.7%) in the ASCVD cohort and 42,172 patients (7.1%) in the diabetes cohort. (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:940 / 951
页数:12
相关论文
共 50 条
  • [31] Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
    Cavallari, Ilaria
    Delli Veneri, Alessia
    Maddaloni, Ernesto
    Melfi, Rosetta
    Patti, Giuseppe
    Napoli, Nicola
    Pozzilli, Paolo
    Di Sciascio, Germano
    CURRENT DIABETES REPORTS, 2018, 18 (12)
  • [32] Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
    Ilaria Cavallari
    Alessia Delli Veneri
    Ernesto Maddaloni
    Rosetta Melfi
    Giuseppe Patti
    Nicola Napoli
    Paolo Pozzilli
    Germano Di Sciascio
    Current Diabetes Reports, 2018, 18
  • [33] Impact of Lipid Lowering Therapies on the Primary Prevention of Atherosclerotic Cardiovascular Disease
    Akruti P. Prabhakar
    Deepak Vedamurthy
    Dinesh K. Kalra
    Current Cardiovascular Risk Reports, 2025, 19 (1)
  • [34] UTILIZATION OF LIPID-LOWERING THERAPY AND LDL-CHOLESTEROL IN PATIENTS WITH PRIOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PRESENTING WITH ACUTE MYOCARDIAL INFARCTION
    Essa, Mohammed
    Lu, Yuan
    Huang, Haocheng
    Desai, Nihar R.
    Spatz, Erica Sarah
    Krumholz, Harlan M.
    Dajani, Abdel
    Mankbadi, Michael
    Kay, Bradley
    Faridi, Kamil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2008 - 2008
  • [35] Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
    Quek, Ruben G. W.
    Fox, Kathleen M.
    Wang, Li
    Li, Lu
    Gandra, Shravanthi R.
    Wong, Nathan D.
    BMJ OPEN DIABETES RESEARCH & CARE, 2015, 3 (01)
  • [36] The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study
    Tsai, Ming-Hsien
    Chen, Mingchih
    Huang, Yen-Chun
    Liou, Hung-Hsiang
    Fang, Yu-Wei
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [37] Lipid-lowering therapy for the prevention of atherosclerotic cardiovascular disease: guidelines and clinical practice
    Lucchi, Tiziano
    Cesari, Matteo
    Vergani, Carlo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (04) : 256 - 263
  • [38] Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular disease
    Wang, Yuexi
    Du, Xiaohong
    Zhao, Ruifen
    Niu, Juan
    Wang, Haixu
    Li, Jing
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2021, 50 (06) : 474 - 480
  • [39] UNDERUSE OF LIPID-LOWERING THERAPIES IN PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) IN 2021: RESULTS FROM THE FRENCH NATIONWIDE CLAIMS DATABASE
    Wargny, Matthieu
    Goronflot, Thomas
    Duret, Stephanie
    Pouriel, Mathilde
    Bastien, Alexandre
    Prax, Julie
    Leux, Christophe
    Beliard, Sophie
    Costa, Nadege
    Ferrieres, Jean
    Cariou, Bertrand
    ATHEROSCLEROSIS, 2024, 395
  • [40] LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
    Catapano, A. L.
    Manu, M. C.
    Burden, A.
    Ray, K. K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2373 - 2373